Drug for preventing and/or treating dementia

Abstract

Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.

The invention claimed is: 
     
       1. A method for improving memory disorders and behavioral and psychological symptoms of dementia (BPSD) in a patient with dementia comprising administering to the patient a combination of an effective amount of (a) a carbostyril derivative represented by formula (1) 
       
         
           
           
               
               
           
         
       
       wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus, or a salt thereof, and (b) an effective amount of dihydroquercetin or a salt thereof. 
     
     
       2. The method according to  claim 1 , wherein the carbostyril derivative is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril. 
     
     
       3. The method according to  claim 1 , wherein the dementia is Alzheimer-type dementia, Lewy body dementia, frontotemporal dementia, cerebrovascular dementia, Parkinson's disease, Down's syndrome, or Huntington's disease. 
     
     
       4. A method for improving spatial memory disorders in a patient with dementia comprising administering to the patient a combination of (a) an effective amount of a carbostyril derivative represented by formula (1) 
       
         
           
           
               
               
           
         
       
       wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus, or a salt thereof, and (b) an effective amount of dihydroquercetin or a salt thereof. 
     
     
       5. The method according to  claim 4 , wherein the carbostyril derivative is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril. 
     
     
       6. The method according to  claim 4 , wherein the dementia is Alzheimer-type dementia, Lewy body dementia, frontotemporal dementia, cerebrovascular dementia, Parkinson's disease, Down's syndrome, or Huntington's disease. 
     
     
       7. A method for suppressing excitatory action in a patient with dementia comprising administering to the patient a combination of (a) an effective amount of a carbostyril derivative represented by formula (1) 
       
         
           
           
               
               
           
         
       
       wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus, or a salt thereof, and (b) an effective amount of dihydroquercetin or a salt thereof. 
     
     
       8. The method according to  claim 7 , wherein the carbostyril derivative is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril. 
     
     
       9. The method according to  claim 7 , wherein the dementia is Alzheimer-type dementia, Lewy body dementia, frontotemporal dementia, cerebrovascular dementia, Parkinson's disease, Down's syndrome, or Huntington's disease.